Clinical Trial Detail

NCT ID NCT02841540
Title Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors H3 Biomedicine Inc.
Indications

chronic myelomonocytic leukemia

myelodysplastic syndrome

acute myeloid leukemia

Therapies

H3B-8800

Age Groups: adult senior

Additional content available in CKB BOOST